<p>TScan Therapeutics（纳斯达克代码：TCRX - 获取免费报告）于周二发布了季度财报。该公司报告的每股收益（EPS）为（$0.28），超出分析师一致预期的（$0.35）$0.07，FiscalAI 报道。该季度的收入为 251 万美元，而一致预期为 198 万美元。TScan Therapeutics 的股本回报率为负的 63.33%，净利润率为负的 1,964.88%。</p>
<p>获取 <strong>TScan Therapeutics</strong> 的提醒：</p>
<h2>TScan Therapeutics 股票表现</h2>
<p>周三午盘交易中，TCRX 股票下跌$0.04，报$1.18。该公司的交易量为 414,920 股，而其平均交易量为 507,574 股。该公司的市值为 6697 万美元，市盈率为-1.08，贝塔系数为 1.00。公司的债务与股本比率为 0.18，速动比率为 7.06，流动比率为 7.06。TScan Therapeutics 的 12 个月低点为$1.02，12 个月高点为$5.56。该股票的 50 日移动平均价格为$1.88，200 日移动平均价格为$1.71。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些研究分析师最近对该公司进行了评估。Wedbush 在 8 月 12 日的报告中重申了 “跑赢大盘” 的评级，并对 TScan Therapeutics 的股票设定了$7.00 的目标价。Weiss Ratings 在 10 月 8 日的报告中重申了对 TScan Therapeutics 股票的 “卖出（d-）” 评级。BTIG Research 在 11 月 4 日的研究报告中将 TScan Therapeutics 的股票评级从 “买入” 下调至 “中性”。最后，Needham &amp; Company LLC 在 11 月 4 日的研究报告中将 TScan Therapeutics 的股票目标价从$9.00 下调至$6.00，并对该股票设定了 “买入” 评级。五位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价为$7.20。</p>
<p><strong>查看我们关于 TCRX 的最新研究报告</strong></p>
<h2>对 TScan Therapeutics 的对冲基金看法</h2>
<p>机构投资者最近买入和卖出了该公司的股票。Vanguard Group Inc.在第三季度将其在 TScan Therapeutics 的持股增加了 7.8%。Vanguard Group Inc.现在拥有 2317916 股该公司的股票，价值 421.9 万美元，此前在上个季度又购买了 168540 股。Militia Capital Partners LP 在第二季度购买了 TScan Therapeutics 的新股份，价值约为 137,000 美元。Bridgeway Capital Management LLC 在第二季度将其在 TScan Therapeutics 的持股增加了 35.7%。Bridgeway Capital Management LLC 现在拥有 153700 股该公司的股票，价值 223,000 美元，此前在此期间又收购了 40400 股。美国银行在第二季度将其在 TScan Therapeutics 的持股增加了 28.0%。美国银行现在拥有 217967 股该公司的股票，价值 316,000 美元，此前在此期间又购买了 47617 股。最后，Jane Street Group LLC 在第二季度购买了 TScan Therapeutics 的新股份，价值 309,000 美元。对冲基金和其他机构投资者持有该公司 82.83% 的股票。</p>
<h2>关于 TScan Therapeutics</h2>
<p>（获取免费报告）</p>
<p>TScan Therapeutics, Inc.是一家临床阶段的生物制药公司，开发 T 细胞受体工程 T 细胞（TCR-T）疗法，用于治疗美国癌症患者。该公司的主要产品候选包括 TSC-100 和 TSC-101，目前正在进行针对血液恶性肿瘤患者的 I 期临床试验，以消除残余疾病并防止同种异体造血干细胞移植后的复发。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 TScan Therapeutics</li>
<li>价值投资：2022 年是个好策略吗？提示：永远</li>
<li>Papa John's 27 亿美元收购提议：未开发价值的价格</li>
<li>航空公司股票 - 现在值得购买的顶级航空公司股票</li>
<li>高通是上涨 40% 还是下跌 20%？两种逆向观点</li>
<li>股票分析师评级和加拿大分析师评级</li>
<li>Guardian Pharmacy 股票因第三季度强劲表现和乐观预测而上涨</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VENSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VENSWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 TScan Therapeutics 吗？</h2>
<p>在你考虑 TScan Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 TScan Therapeutics 并不在名单上。</p>
<p>虽然 TScan Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

TCRX

<p>TScan Therapeutics 报告了季度收益，每股收益超出预期 0.07 美元。该公司发布的每股收益为（0.28）美元，超过了市场共识的（0.35）美元。收入为 251 万美元，高于预期的 198 万美元。尽管股本回报率和净利润率为负，分析师的评级却各不相同，整体评级为适度买入，平均目标价为 7.20 美元。机构投资者持有 82.83% 的股份。TScan 开发用于癌症治疗的 TCR-T 疗法</p>

<p>TScan Therapeutics (NASDAQ:TCRX - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.07, FiscalAI reports. The business had revenue of $2.51 million during the quarter, compared to the consensus estimate of $1.98 million. TScan Therapeutics had a negative return on equity of 63.33% and a negative net margin of 1,964.88%.</p>
<div class="lb-trans"><p>TScan Therapeutics（纳斯达克代码：TCRX - 获取免费报告）于周二发布了季度财报。该公司报告的每股收益（EPS）为（$0.28），超出分析师一致预期的（$0.35）$0.07，FiscalAI 报道。该季度的收入为 251 万美元，而一致预期为 198 万美元。TScan Therapeutics 的股本回报率为负的 63.33%，净利润率为负的 1,964.88%。</p>
</div><p>Get <strong>TScan Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>TScan Therapeutics</strong> 的提醒：</p>
</div><h2>TScan Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>TScan Therapeutics 股票表现</h2>
</div><p>TCRX stock traded down $0.04 during mid-day trading on Wednesday, hitting $1.18. The company had a trading volume of 414,920 shares, compared to its average volume of 507,574. The firm has a market cap of $66.97 million, a PE ratio of -1.08 and a beta of 1.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 7.06 and a current ratio of 7.06. TScan Therapeutics has a 12 month low of $1.02 and a 12 month high of $5.56. The stock's fifty day moving average price is $1.88 and its two-hundred day moving average price is $1.71.</p>
<div class="lb-trans"><p>周三午盘交易中，TCRX 股票下跌$0.04，报$1.18。该公司的交易量为 414,920 股，而其平均交易量为 507,574 股。该公司的市值为 6697 万美元，市盈率为-1.08，贝塔系数为 1.00。公司的债务与股本比率为 0.18，速动比率为 7.06，流动比率为 7.06。TScan Therapeutics 的 12 个月低点为$1.02，12 个月高点为$5.56。该股票的 50 日移动平均价格为$1.88，200 日移动平均价格为$1.71。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of research analysts have recently weighed in on the company. Wedbush restated an &#34;outperform&#34; rating and issued a $7.00 target price on shares of TScan Therapeutics in a report on Tuesday, August 12th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of TScan Therapeutics in a report on Wednesday, October 8th. BTIG Research lowered shares of TScan Therapeutics from a &#34;buy&#34; rating to a &#34;neutral&#34; rating in a research note on Tuesday, November 4th. Finally, Needham &amp; Company LLC dropped their price target on shares of TScan Therapeutics from $9.00 to $6.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, November 4th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and an average target price of $7.20.</p>
<div class="lb-trans"><p>一些研究分析师最近对该公司进行了评估。Wedbush 在 8 月 12 日的报告中重申了 “跑赢大盘” 的评级，并对 TScan Therapeutics 的股票设定了$7.00 的目标价。Weiss Ratings 在 10 月 8 日的报告中重申了对 TScan Therapeutics 股票的 “卖出（d-）” 评级。BTIG Research 在 11 月 4 日的研究报告中将 TScan Therapeutics 的股票评级从 “买入” 下调至 “中性”。最后，Needham &amp; Company LLC 在 11 月 4 日的研究报告中将 TScan Therapeutics 的股票目标价从$9.00 下调至$6.00，并对该股票设定了 “买入” 评级。五位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价为$7.20。</p>
</div><p><strong>Check Out Our Latest Research Report on TCRX</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 TCRX 的最新研究报告</strong></p>
</div><h2>Hedge Funds Weigh In On TScan Therapeutics</h2>
<div class="lb-trans"><h2>对 TScan Therapeutics 的对冲基金看法</h2>
</div><p>Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of TScan Therapeutics by 7.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,317,916 shares of the company's stock valued at $4,219,000 after buying an additional 168,540 shares during the last quarter. Militia Capital Partners LP purchased a new stake in TScan Therapeutics in the 2nd quarter worth about $137,000. Bridgeway Capital Management LLC raised its stake in TScan Therapeutics by 35.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 153,700 shares of the company's stock valued at $223,000 after acquiring an additional 40,400 shares during the period. Bank of America Corp DE raised its position in shares of TScan Therapeutics by 28.0% in the second quarter. Bank of America Corp DE now owns 217,967 shares of the company's stock valued at $316,000 after purchasing an additional 47,617 shares during the period. Finally, Jane Street Group LLC bought a new position in shares of TScan Therapeutics in the second quarter worth $309,000. Hedge funds and other institutional investors own 82.83% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近买入和卖出了该公司的股票。Vanguard Group Inc.在第三季度将其在 TScan Therapeutics 的持股增加了 7.8%。Vanguard Group Inc.现在拥有 2317916 股该公司的股票，价值 421.9 万美元，此前在上个季度又购买了 168540 股。Militia Capital Partners LP 在第二季度购买了 TScan Therapeutics 的新股份，价值约为 137,000 美元。Bridgeway Capital Management LLC 在第二季度将其在 TScan Therapeutics 的持股增加了 35.7%。Bridgeway Capital Management LLC 现在拥有 153700 股该公司的股票，价值 223,000 美元，此前在此期间又收购了 40400 股。美国银行在第二季度将其在 TScan Therapeutics 的持股增加了 28.0%。美国银行现在拥有 217967 股该公司的股票，价值 316,000 美元，此前在此期间又购买了 47617 股。最后，Jane Street Group LLC 在第二季度购买了 TScan Therapeutics 的新股份，价值 309,000 美元。对冲基金和其他机构投资者持有该公司 82.83% 的股票。</p>
</div><h2>About TScan Therapeutics</h2>
<div class="lb-trans"><h2>关于 TScan Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.</p>
<div class="lb-trans"><p>TScan Therapeutics, Inc.是一家临床阶段的生物制药公司，开发 T 细胞受体工程 T 细胞（TCR-T）疗法，用于治疗美国癌症患者。该公司的主要产品候选包括 TSC-100 和 TSC-101，目前正在进行针对血液恶性肿瘤患者的 I 期临床试验，以消除残余疾病并防止同种异体造血干细胞移植后的复发。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than TScan Therapeutics</li>
<li>Value Investing: Is it a Good Strategy in 2022? Hint: Always</li>
<li>Papa John's $2.7 Billion Takeover Bid: A Price on Untapped Value</li>
<li>Airline Stocks - Top Airline Stocks to Buy Now</li>
<li>Is Qualcomm Up 40% or Down 20%? 2 Contrarian Takes</li>
<li>Stock Analyst Ratings and Canadian Analyst Ratings</li>
<li>Guardian Pharmacy Stock Pops on Q3 Strength and Upbeat Forecast</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 TScan Therapeutics</li>
<li>价值投资：2022 年是个好策略吗？提示：永远</li>
<li>Papa John's 27 亿美元收购提议：未开发价值的价格</li>
<li>航空公司股票 - 现在值得购买的顶级航空公司股票</li>
<li>高通是上涨 40% 还是下跌 20%？两种逆向观点</li>
<li>股票分析师评级和加拿大分析师评级</li>
<li>Guardian Pharmacy 股票因第三季度强劲表现和乐观预测而上涨</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VENSWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=TCRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in TScan Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 TScan Therapeutics 吗？</h2>
</div><p>Before you consider TScan Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 TScan Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TScan Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 TScan Therapeutics 并不在名单上。</p>
</div><p>While TScan Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 TScan Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

TScan Therapeutics（纳斯达克股票代码：TCRX）公布季度财报，每股收益比预期高出 0.07 美元